Support for a two-year program of industrial action which UK general practitioners are threatening to undertake has been announced by the Council of the British Medical Association. The General medical Services Committee, which represents the GPs, says the aim of the program would be to "hit the government where it hurts most - in the pocket."
The GMSC drew up the plan because of deadlock with the government over arrangements for doctors' out-of-hours working, and anger at tactics employed by the government to get the issue resolved. The GMSC is keeping details of the program secret, but the plan is to introduce at least one new measure per month over the next two years, for the duration of the dispute. Under the law, GPs must be balloted by the GMSC before the sanctions program can be advocated.
GP magazine says the program, which would be wide-ranging, aims to increase pressure on the government, damage controls on public spending and protect individuals from risk. Within prescribing, Gp action could include: prescribing branded drugs only (no generics); issuing repeat prescriptions each week instead of every three months to patients who are exempt from prescription charges; prescribing in larger quantities; and boycotting the new FP10. George Rae, deputy chairman of the GMSC prescribing subcommittee, told GP that the sanctions would work without rebounding on GPs or affecting care.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze